O
Opus Genetics | Ocuphire Pharma
Clinical-stage gene therapies for inherited retinal diseases
About Opus Genetics | Ocuphire Pharma
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on the development of gene therapies and ophthalmic treatments to address rare and debilitating inherited retinal diseases (IRDs) and other vision disorders. Formed through the all-stock acquisition of Opus Genetics by Ocuphire Pharma in October 2024, the combined entity adopted the Opus Genetics name and Nasdaq ticker symbol “IRD” to reflect its strategic focus on transformative genetic medicines for vision loss.
The company’s core mission is to restore and preserve vision by addressing the underlying genetic causes of severe retinal disorders that currently lack effective therapies. Its pipeline centers on multiple adeno-associated virus (AAV)-based gene therapy candidates, including programs targeting Leber congenital amaurosis (LCA5), BEST1-related diseases, and other mutations associated with retinitis pigmentosa and related conditions. These one-time, potentially durable treatments aim to deliver healthy copies of defective genes directly to retinal cells, offering hope for patients with historically untreatable forms of blindness.
In addition to its gene therapy portfolio, Opus Genetics continues to develop phentolamine ophthalmic solution 0.75%, an approved small-molecule therapy originally advanced by Ocuphire, which is being evaluated in Phase 3 clinical trials for conditions such as presbyopia and low-light vision disturbances following keratorefractive surgery. The company also collaborates with strategic partners to further small-molecule and biologic ophthalmic programs where appropriate.
Opus Genetics serves patients, clinicians, and the broader retinal disease community worldwide. Its value proposition lies in combining world-class gene therapy innovation—rooted in scientific expertise and supported by leading researchers and clinicians—with clinical development experience and capital resources to accelerate regulatory milestones and broaden patient access. The company’s work occurs within a rapidly evolving biotechnology landscape in which genetic medicines are increasingly recognized for their potential to deliver durable, targeted treatments for conditions once considered untreatable.
Headquartered in Research Triangle Park/Durham, North Carolina, Opus Genetics is led by a seasoned management team and board with deep experience in ophthalmology, gene therapy, and translational science. The company positions itself at the intersection of cutting-edge biotechnology and patient-centric innovation, addressing substantial unmet medical needs in rare ophthalmic diseases while pursuing broader applications that could impact millions of patients globally.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2018
- Headquarters
- Durham, United States
- Listing
- IPO 2004
- Employees
- 44
- Open positions
- 3
- Dealroom signal
- 94.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, Seal of Excellence EC, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 1 company, latest Oct 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Apr 2026 | $5M | — | Oberland Capital | ↗ |
| GRANTOther financing | Apr 2026 | $35M | — | Oberland Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $15M | +4.7% | −$37M | -245.8% |
| 2025 | $14M | +29.1% | −$37M | -257.5% |
| 2024 | $11M | -42.3% | −$30M | -269.2% |
| 2023 | $19M | -52.2% | −$8.7M | -45.8% |
| 2022 | $40M | +6665.7% | $18M | 45.7% |
| 2021 | $589K | — | −$23M | -3880.8% |
| 2020 | — | — | −$9.4M | — |
Growth signals
Latest recorded traffic for Opus Genetics | Ocuphire Pharma is 7.1K monthly website visits, down 16.5% over the last three months. Opus Genetics | Ocuphire Pharma's team grew 46.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Opus Genetics | Ocuphire Pharma in the Durham ecosystem
The Opus Genetics | Ocuphire Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
National Eye Institute
Retinal Degeneration Fund
Series B and later11 investors entered at this stage
Michigan Angel Fund
Blue Water Angels
BELLE Capital
Grand Angels
Ann Arbor Angels
Perceptive Advisors- NMNantahala Capital Management
- GMGeorge Magrath
Cam Gallagher
Balyasny Asset Management
Oberland Capital
Other known investors8 additional known investors
Adage Capital
Marshall Wace- TPTrails Edge Capital Partners
Altium Capital Management
Belle Fund
Biosciences Research and Commercialization Center
ID Ventures
Michigan Capital Network
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Opus Genetics | Ocuphire Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Opus Genetics | Ocuphire Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










